Galapagos: Investor Presentation (Galapagos) - Apr 19, 2014 - "Phase 2 studies with GSK2586184"; "Phase 2 in psoriasis met primary endpoint"; "Significantly higher proportion met targeted PASI75% at 400 mg BID dose"; "Most common adverse event was headache"
P2 data • Immunology
|